Skip to main navigation Skip to search Skip to main content

International Survey of ALS Experts about Critical Questions for Assessing Patients with ALS

Mamede De Carvalho*, Adam Ryczkowski, Peter Andersen, Marta Gromicho, Julian Grosskreutz, Magdalena Kuźma-Kozakiewicz, Susanne Petri, Maria Piotrkiewicz, Gabriel Miltenberger Miltenyi

*Corresponding author for this work

Abstract

Objective: To define an applicable dataset for ALS patient registries we weighted specific clinical items as scored by worldwide ALS experts. Methods: Sixty participants were invited based on relevant clinical work, publications and personal acquaintance. They rated 160 clinical items consensually agreed by the members of our project, incorporating specialists from five European Centres. Scoring scheme was defined as: 1–essential; 2–important; 3–not very important. A mixed effect model was applied to rank items and to find possible correlations with geographical region (Europe vs. outside Europe). Results: We received 40 responses, 20 from Europe and 20 from outside; 42/160 data were scored as essential by >50% of the respondents, including: date of birth, gender, date of disease onset, date of diagnosis, ethnicity, region of onset, predominant upper neuron (UMN) or lower motor neuron (LMN) impairment, proximal versus distal weakness, respiratory symptoms, dysarthria, weight loss, signs of LMN/UMN involvement, emotional incontinence, cognitive changes, respiratory signs, neck weakness, body mass index, ALSFRS-R at entry, ALSFRS-R subscores at entry, timing and pattern of spreading and staging, electromyography, spirometry, MRI, CK level, riluzole intake, genetic background, history of physical exercise and previous and current main occupation. Four components were scored as non-relevant, including place of birth, blood pressure and pain at onset. There was no significant difference between regions (European vs. non-European countries). Conclusions: Our study identified a consensual set of clinical data with 42 specific items that can be used as a minimal data set for patient registers and for clinical trials.

Original languageEnglish
JournalAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Volume18
Issue number7-8
Pages (from-to)505-510
Number of pages6
ISSN2167-8421
DOIs
Publication statusPublished - 02.10.2017
Externally publishedYes

Funding

This is an EU Joint Programme–Neurodegenerative Disease Research (JPND) project. The project is supported through the following funding organisations under the aegis of JPND-www.jpnd.eu : Germany, Bundesministerium für Bildung und Forschung (BMBF); Poland, Narodowe Centrum Badań i Rozwoju (NCBiR); Portugal, Fundação a Ciência e a Tecnologia (FCT); Sweden, Vetenskapsrådet (VR). This is an EU Joint Programme – Neurodegenerative Disease Research (JPND) project. The project is supported through the following funding organisations under the aegis of JPND-www.jpnd.eu: Germany, Bundesministerium für Bildung und Forschung (BMBF); Poland, Narodowe Centrum Badań i Rozwoju (NCBiR); Portugal, Fundac¸ão a Ciência e a Tecnologia (FCT); Sweden, Vetenskapsrådet (VR).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Research Areas and Centers

  • Centers: Center for Neuromuscular Diseases

Fingerprint

Dive into the research topics of 'International Survey of ALS Experts about Critical Questions for Assessing Patients with ALS'. Together they form a unique fingerprint.

Cite this